Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49


The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S.

Haematologica. 2017 Nov;102(11):1833-1841. doi: 10.3324/haematol.2015.136671. Epub 2017 Jul 27.


Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells.

Zeng Y, Liu B, Rubio MT, Wang X, Ojcius DM, Tang R, Durrbach A, Ru Z, Zhou Y, Lone YC.

PLoS One. 2017 Apr 11;12(4):e0173754. doi: 10.1371/journal.pone.0173754. eCollection 2017.


A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.

Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E.

Clin Cancer Res. 2016 Aug 15;22(16):4133-44. doi: 10.1158/1078-0432.CCR-16-0044. Epub 2016 Mar 22.


Characterization of effector components from the humoral and cellular immune response stimulated by melanoma cells exhibiting modified IGF-1 expression.

Zhu C, Trabado S, Fan Y, Trojan J, Lone YC, Giron-Michel J, Duc HT.

Biomed Pharmacother. 2015 Mar;70:53-7. doi: 10.1016/j.biopha.2015.01.002. Epub 2015 Jan 12.


Predictive immunogenicity of Refacto AF.

Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2014 Jul;20(4):486-92. doi: 10.1111/hae.12348. Epub 2013 Dec 30.


Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O.

Clin Cancer Res. 2012 Nov 15;18(22):6284-95. doi: 10.1158/1078-0432.CCR-12-0896. Epub 2012 Oct 2.


Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.

Ru Z, Xiao W, Pajot A, Kou Z, Sun S, Maillere B, Zhao G, Ojcius DM, Lone YC, Zhou Y.

PLoS One. 2012;7(3):e32247. doi: 10.1371/journal.pone.0032247. Epub 2012 Mar 5.


A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E.

Blood. 2011 Nov 3;118(18):4853-62. doi: 10.1182/blood-2011-01-329656. Epub 2011 Sep 9.


Characterization of the specific CD4+ T cell response against the F protein during chronic hepatitis C virus infection.

Gao DY, Jin GD, Yao BL, Zhang DH, Gu LL, Lu ZM, Gong Q, Lone YC, Deng Q, Zhang XX.

PLoS One. 2010 Dec 6;5(12):e14237. doi: 10.1371/journal.pone.0014237.


Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo.

Bayard F, Malmassari S, Deng Q, Lone YC, Michel ML.

Vaccine. 2010 May 14;28(22):3818-26. doi: 10.1016/j.vaccine.2010.03.026. Epub 2010 Mar 31.


Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.

Deng Q, Mancini-Bourgine M, Zhang X, Cumont MC, Zhu R, Lone YC, Michel ML.

Hepatology. 2009 Nov;50(5):1380-91. doi: 10.1002/hep.23150.


Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells.

Chevaliez S, Balanant J, Maillard P, Lone YC, Lemonnier FA, Delpeyroux F.

Virology. 2008 Nov 25;381(2):203-14. doi: 10.1016/j.virol.2008.08.006. Epub 2008 Sep 27.


A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspé G, Fournillier A.

Vaccine. 2008 May 12;26(20):2471-81. doi: 10.1016/j.vaccine.2008.03.028. Epub 2008 Apr 1.


Stimulation of anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9.

Trabado S, Van Binh PN, Martin C, Lafarge-Frayssinet C, Lone YC, Trojan J, Warnet JM, Duc HT.

Biomed Pharmacother. 2007 Sep;61(8):494-8. Epub 2007 Aug 7.


B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, Fridman WH, Lemonnier F, Johannes L, Tartour E.

J Immunol. 2007 Sep 1;179(5):3371-9.


The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1.

Pajot A, Schnuriger A, Moris A, Rodallec A, Ojcius DM, Autran B, Lemonnier FA, Lone YC.

Eur J Immunol. 2007 Sep;37(9):2635-44.


Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients.

Mancini-Bourgine M, Bayard F, Soussan P, Deng Q, Lone YC, Kremsdorf D, Michel ML.

J Virol. 2007 May;81(10):4963-72. Epub 2007 Mar 14.


Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects.

Pajot A, Michel ML, Mancini-Bourgine M, Ungeheuer MN, Ojcius DM, Deng Q, Lemonnier FA, Lone YC.

Microbes Infect. 2006 Oct;8(12-13):2783-90. Epub 2006 Sep 12.


Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines.

Michel M, Lone YC, Centlivre M, Roux P, Wain-Hobson S, Sala M.

Vaccine. 2007 Feb 26;25(10):1901-11. Epub 2006 Aug 22.


Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides.

Fournillier A, Dupeyrot P, Martin P, Parroche P, Pajot A, Chatel L, Fatmi A, Gerossier E, Bain C, Lone YC, Trépo C, Inchauspé G.

Vaccine. 2006 Apr 12;24(16):3153-64. Epub 2006 Jan 31.


In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus.

Malmassari S, Lone YC, Zhang M, Transy C, Michel ML.

Microbes Infect. 2005 Apr;7(4):626-34. Epub 2005 Mar 16.


A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.

Pajot A, Michel ML, Fazilleau N, Pancré V, Auriault C, Ojcius DM, Lemonnier FA, Lone YC.

Eur J Immunol. 2004 Nov;34(11):3060-9.


Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.

Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone YC, Inchauspé G, Fournillier A.

J Med Virol. 2004 Nov;74(3):397-405.


Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen.

Hernández J, Schoeder K, Blondelle SE, Pons FG, Lone YC, Simora A, Langlade-Demoyen P, Wilson DB, Zanetti M.

Eur J Immunol. 2004 Aug;34(8):2331-41.


Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules.

Pajot A, Pancré V, Fazilleau N, Michel ML, Angyalosi G, Ojcius DM, Auriault C, Lemonnier FA, Lone YC.

Int Immunol. 2004 Sep;16(9):1275-82. Epub 2004 Jul 12.


Identification of HLA-A*0201-restricted cytotoxic T-cell epitopes of Trypanosoma cruzi TcP2beta protein in HLA-transgenic mice and patients.

Garcia F, Sepulveda P, Liegeard P, Gregoire J, Hermann E, Lemonnier F, Langlade-Demoyen P, Hontebeyrie M, Lone YC.

Microbes Infect. 2003 Apr;5(5):351-9.


Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.

Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G.

J Virol. 2002 Dec;76(24):12735-46.


In vivo priming of HIV-specific CTLs determines selective cross-reactive immune responses against poorly immunogenic HIV-natural variants.

Boissonnas A, Bonduelle O, Antzack A, Lone YC, Gache C, Debre P, Autran B, Combadière B.

J Immunol. 2002 Oct 1;169(7):3694-9.


Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M.

Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12275-80. Epub 2002 Sep 6.


Mutational analysis and molecular modeling of the binding of Staphylococcus aureus enterotoxin C2 to a murine T cell receptor Vbeta10 chain.

Rössle SC, Bisch PM, Lone YC, Abastado JP, Kourilsky P, Bellio M.

Eur J Immunol. 2002 Aug;32(8):2172-8.


Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope.

Brinster C, Muguet S, Lone YC, Boucreux D, Renard N, Fournillier A, Lemonnier F, Inchauspé G.

Hepatology. 2001 Dec;34(6):1206-17.


Soluble HLA-G: purification from eukaryotic transfected cells and detection by a specific ELISA.

Fournel S, Aguerre-Girr M, Campan A, Salauze L, Berrebi A, Lone YC, Lenfant F, Le Bouteiller P.

Am J Reprod Immunol. 1999 Jul;42(1):22-9.


In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes.

Lone YC, Motta I, Mottez E, Guilloux Y, Lim A, Demay F, Levraud JP, Kourilsky P, Abastado JP.

J Immunother. 1998 Jul;21(4):283-94.


Role of the CDR1 region of the TCR beta chain in the binding to purified MHC-peptide complex.

Lone YC, Bellio M, Prochnicka-Chalufour A, Ojcius DM, Boissel N, Ottenhoff TH, Klausner RD, Abastado JP, Kourilsky P.

Int Immunol. 1994 Oct;6(10):1561-5.


Major contribution of the beta chain to the antigen specificity of a T cell receptor.

Lone YC, Ojcius DM, Bellio M, Kourilsky P, Abastado JP.

C R Acad Sci III. 1994 Jul;317(7):645-51.


Humanization of mouse anti-human IL-2 receptor antibody B-B10.

Nakatani T, Lone YC, Yamakawa J, Kanaoka M, Gomi H, Wijdenes J, Noguchi H.

Protein Eng. 1994 Mar;7(3):435-43.


Action of in situ nitroglycerin on upper anal canal pressure of patients with terminal constipation. A pilot study.

Guillemot F, Leroi H, Lone YC, Rousseau CG, Lamblin MD, Cortot A.

Dis Colon Rectum. 1993 Apr;36(4):372-6.


Nitroglycerin in situ reduces upper anal canal pressure.

Guillemot F, Lone YC, Leroi H, Lamblin MD, Cortot A.

Dig Dis Sci. 1992 Jan;37(1):155. No abstract available.


Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators.

Cherkaoui Malki M, Lone YC, Corral-Debrinski M, Latruffe N.

Biochem Biophys Res Commun. 1990 Dec 31;173(3):855-61.


Expression of the rat L-type pyruvate kinase gene from its dual erythroid- and liver-specific promoter in transgenic mice.

Tremp GL, Boquet D, Ripoche MA, Cognet M, Lone YC, Jami J, Kahn A, Daegelen D.

J Biol Chem. 1989 Nov 25;264(33):19904-10.


Structure of the rat L-type pyruvate kinase gene.

Cognet M, Lone YC, Vaulont S, Kahn A, Marie J.

J Mol Biol. 1987 Jul 5;196(1):11-25.


Tissue-specific heterogeneity of the 3'-untranslated region of L-type pyruvate kinase mRNAs.

Marie J, Simon MP, Lone YC, Cognet M, Kahn A.

Eur J Biochem. 1986 Jul 1;158(1):33-41.


Complete nucleotide and deduced amino acid sequences of rat L-type pyruvate kinase.

Lone YC, Simon MP, Kahn A, Marie J.

FEBS Lett. 1986 Jan 20;195(1-2):97-100.

Supplemental Content

Support Center